- CureToday.com
- OncLive.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
Jason M. Broderick | Authors
Articles
Numerical Boost in OS With TAK-700 Misses Threshold for Significance in mHSPC
June 09, 2021
Despite failure to reach the primary end point of statistically significant overall survival benefit, TAK-700 plus androgen-deprivation therapy for metastatic hormone-sensitive prostate cancer may be a valid treatment option for some patients.
TURBT With Nivolumab and Chemo Promising Bladder-Sparing Strategy in MIBC
June 08, 2021
As a bladder-sparing treatment strategy, transurethral resection of the bladder tumor with nivolumab and chemotherapy showed promise for patients with muscle-invasive bladder cancer.
Long-Term Survival Benefit Reported for Pembrolizumab/Axitinib Combo in RCC
June 07, 2021
As frontline therapy, pembrolizumab plus axitinib led to a statistically significant survival benefit over standard-of-care therapy, according to data presented at the 2021 ASCO Annual Meeting.
VISION Trail Results Indicate Benefit of 177Lu-PSMA-617A Added to Standard Therapy
June 03, 2021
A 40% reduction in the risk of death was observed when 177Lu-PSMA-617A was added to standard of care therapy in patients with PSMA-positive metastatic castration-resistant prostate cancer.
PSMA-Targeted 177Lu-PSMA-617 Heads for Regulatory Approval in mCRPC
April 22, 2021
Scott T. Tagawa, MD, considers data for the novel PSMA-targeted radiopharmaceutical 177Lu-PSMA-617.
Talazoparib Most Likely to Inhibit Response in Men With Heavily Pretreated mCRPC
April 15, 2021
Patients with germline and/or homozygous tumor DNA damage response alterations among male patients with heavily pretreated metastatic castration-resistant prostate cancer were most likely to respond to treatment with the PARP inhibitor talazoparib.
Study Finds Healthy Lifestyle May Lower Risks for Lethal Prostate Cancer in Men with Genetic Susceptibility
April 10, 2021
Maintaining a healthy lifestyle mitigated the genetic risk for lethal prostate cancer in men with high genetic risk.
Expert Explores the Current Status of Radium-223 Use in Castration-Resistant Prostate Cancer
March 28, 2021
During a presentation at the 14th Annual New York GU Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Scott T. Tagawa, MD, reviewed important findings related to radium-223 and its use in patients with castration-resistant prostate cancer.
PSMA PET Imaging Agent 18F-DCFPyL Enables Better Detection of Localized Metastatic Lesions
February 14, 2021
Findings from the phase 3 CONDOR trial support the use of the PSMA PET imaging agent 18F-DCFPyL as the FDA prepares to make a decision on a new drug application regarding its use.
Abiraterone Acetate and Prednisone Plus Apalutamide Reduced Risk of Progression, Death for Patients with mCRPC
February 12, 2021
For patients with chemotherapy-naïve metastatic castration-resistant prostate cancer receiving androgen deprivation therapy, abiraterone acetate and prednisone plus the addition of apalutamide reduced the risk of radiographic progression or death by 30%.